Patent · US Active

Combination therapies of HDAC inhibitors and PD-L1 inhibitors

US11535670B2 · kind B2 · utility

0Cited by
127References
12Claims
0Family size

Assignee

Inventors

Key dates

Filing dateAug 14, 2019
Grant dateDec 27, 2022
Priority date—
Expiry dateDec 22, 2040

Classification

  • Technology area (CPC C)Chemistry; Metallurgy
  • CPC primaryC07K2317/76
  • WIPO fieldPharmaceuticals
  • WIPO sectorChemistry

Abstract

Provided herein are combinations that include an HDACi and a PD-L1 inhibitor that are useful for treating cancer, including cancer resistant to PD-1 inhibitors.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.